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Available online 26 November 2017Midkine is a pleiotropic factor, which is involved in angiogenesis. However, its mode of action in this process is
still ill deﬁned. The function of midkine in arteriogenesis, the growth of natural bypasses from pre-existing col-
lateral arteries, compensating for the loss of an occluded artery has never been investigated. Arteriogenesis is
an inﬂammatory process, which relies on the proliferation of endothelial cells and smooth muscle cells. We
show that midkine deﬁciency strikingly interferes with the proliferation of endothelial cells in arteriogenesis,
thereby interfering with the process of collateral artery growth. We identiﬁed midkine to be responsible for in-
creased plasma levels of vascular endothelial growth factor A (VEGFA), necessary and sufﬁcient to promote en-
dothelial cell proliferation in growing collaterals. Mechanistically, we demonstrate that leukocyte domiciled
midkinemediates increasedplasma levels of VEGFA relevant for upregulation of endothelial nitric oxide synthase
1 and 3, necessary for proper endothelial cell proliferation, and that non-leukocyte domiciled midkine addition-
ally improves vasodilation.
The data provided on the role ofmidkine in endothelial proliferation are likely to be relevant for both, the process
of arteriogenesis and angiogenesis. Moreover, our data might help to estimate the therapeutic effect of clinically
applied VEGFA in patients with vascular occlusive diseases.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Vascular occlusive disease such as myocardial infarction, stroke or
peripheral artery diseases are still a major cause of morbidity and mor-
tality worldwide. Searching for new, non-invasive options to treat af-
fected patients, much effort is made to understand the molecular
mechanisms of arteriogenesis. Arteriogenesis is a tissue- and even life-
saving process and presents the growth of pre-existing collateral arteri-
oles to natural biological bypasses. It is provoked by increased ﬂuid
shear stress and ismediated by sterile inﬂammation (Chillo et al., 2016).
Midkine (MK) is a retinoic acid inducible cytokine, which is highly
expressed during embryogenesis (Kadomatsu et al., 1990). In the adult-
hood its expression is restricted to certain tissues but strongly induced
during inﬂammatory processes (Badila et al., 2015) such as rheumatoidof Experimental Medicine,
.de (E. Deindl).
. This is an open access article underarthritis, inﬂammatory bowel disease, and multiple sclerosis (for an
overview see (Weckbach et al., 2011)),which are associatedwith angio-
genesis. MK has also been implicated in angiogenesis and hence endo-
thelial cell (EC) proliferation under conditions of tissue ischemia
(Weckbach et al., 2012) and tumor growth (Choudhuri et al., 1997;
Muramaki et al., 2003) as well as in neointima formation (Hayashi
et al., 2005; Horiba et al., 2000). The functional role of MK in angiogen-
esis is still not well deﬁned, however, it was shown that MK induces
chemotaxis of neutrophils and supports neutrophil adhesion during in-
ﬂammation (Takada et al., 1997; Weckbach et al., 2014). Neutrophils
themselves express high levels of MK, but do not release it (Weckbach
et al., 2012; Weckbach et al., 2014; Narita et al., 2008). However, after
stimulation with the chemokine (C-X-C) ligand 1 (CXCL1) neutrophils
release angiogenic growth factor such as vascular endothelial growth
factor A (VEGFA) (Scapini et al., 2004).
The functional role ofMK in arteriogenesis has never been investigat-
ed.Moreover, the functional role of VEGFA in arteriogenesis is controver-
sially discussed (Jazwa et al., 2016). In vitro data from Tzima et al., whothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
238 T. Lautz et al. / EBioMedicine 27 (2018) 237–246identiﬁed the VEGF receptor 2 (VEGFR-2), to be part of a
mechanosensory complex and to be relevant for phosphoinositide 3-
kinase (PI3K) activation, even suggested that VEGFR-2 is ligand-
independent activated in response to shear stress (Tzima et al., 2005).
Here, we demonstrate that leukocyte domiciled midkine controls the
plasma bioavailability of VEGFA, which in turn is relevant for the expres-
sion of neuronal nitric oxide synthase (Nos1) and endothelialNos (Nos3)
(but not inducible Nos (Nos2)) in endothelial cells of collaterals. For
arteriogenesis all three isoform of NOS, namely NOS1, NOS2 and NOS3
are described to be involved, although the function of the individual
NOS is notwell deﬁned (Troidl et al., 2010; Pagel et al., 2011). Exclusively
for NOS3 it has been shown that it mediates vasodilation in growing col-
laterals (Troidl et al., 2010). Here we show that Nos1 or Nos3 expression,
respectively, is essential for collateral endothelial cell proliferation,
whereby both isoforms are likely to be able to substitute for each other.
Collectively, our data provide mechanistic insights into MK-
mediated endothelial cell proliferation, which are likely to be relevant
not only for the process of arteriogenesis, but also for other inﬂammato-
ry processes as well as tumor growth being associated with angiogene-
sis and hence endothelial cell proliferation.
2. Materials and Methods
2.1. Animals and Treatments
All experiments were carried out according to the German animal
legislation guidelines and were approved by the Bavarian Animal Care
and Use Committee. Mice were kept under a 12-hour (h) day and
night cycle with chow and water provided ad libitum.
Micewere treatedwith either 100 μl DETANONOate (CaymanChem-
ical, Ann Arbor, MI) 0.12 mg/ml intraperitoneal once daily in 0.9% NaCl
(saline) (Braun, Melsungen, Germany), with 50 μl recombinant murine
midkine (rmMK) (PeproTech, Rocky Hill, NJ) 0.1 mg/ml subcutaneouslya
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Fig. 1.Mdk−/−mice show reduced perfusion recovery after FAL. (a) Representative images of
(lower panels) mice 7d after FAL (Occ) or sham operation (Sham). Scale bars: 3 mm. (b) Rep
after FAL. (c) Line graph displaying the perfusion ratio (Occ/Sham) of WT andMdk−/−mice b
compared withMdk−/−, two-way ANOVA with Bonferroni's multiple comparison test. Data shtwice daily in saline or with 100 μl recombinant murine VEGFA164
(rmVEGFA) (Sigma-Aldrich, St. Louis, MO) 0.01 mg/ml intraperitoneal
once daily in saline. Control groups received saline only. Sodium nitrite
(Sigma-Aldrich) was applied via drinking water at a concentration of
1 g/l (Kumar et al., 2008; Hannas et al., 2010). Control groups received
normal drinkingwater. Treatment was started 3 days (d) before the sur-
gical procedure and continued until the end of the experiments.
2.2. Femoral Artery Ligation, Laser Doppler Imaging and Bone Marrow
Transplantation
Collateral artery growthwas investigated in amurine hindlimbmodel
(Chillo et al., 2016) using 8- to 10-week-old maleMdk−/− (carrying the
Mdktm1Tmu allele, RRID: MGI:3579532) (Nakamura et al., 1998),
Nos1−/− (B6.129S4-Nos1tm1Plh/J, RRID: IMSR_JAX:002986) (Huang et al.,
1993) mice and appropriate WT controls (C57BL/6J mice, RRID:
IMSR_JAX:000664; Charles River, Sulzfeld, Germany).Mice underwent li-
gation of the right femoral artery distally to the origin of the profunda
femoris branch using a 7-0 silk braided suture (Peasalls Sutures, Somer-
set, Great Britain). During the surgical procedures mice were under gen-
eral anesthesia with a combination of fentanyl (0.05mg/kg bodyweight)
(Janssen-Cilag, Neuss, Germany), midazolam (5.0 mg/kg body weight)
(Ratiopharm, Ulm, Germany) and medetomidine (0.5 mg/kg body
weight) (Pﬁzer, NewYork, NY),whichwas administered subcutaneously.
The left leg underwent sham operation and was used as control. Perfu-
sion of the paws was assessed using a LDI technique (Moor LDI 5061
and Moor Software Version 3.01, Moor Instruments, Remagen,
Germany) under temperature-controlled conditions. The measurements
were conducted before FAL (basal), immediately after FAL (aFAL), 3d
and 7d after FAL. Color-coded images of the paws representing the ﬂux
value were used to calculate the ratio of the tissue perfusion of the oc-
cluded (Occ) to the Sham-operated (Sham) paw. For bonemarrow trans-
plantation see the Supplemental Experimental Procedures.ba
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Heparinized blood gained by cardiac puncture was centrifuged
(2.300g at 4 °C for 20 min) and plasma was stored at−80 °C. Prior to
harvesting superﬁcial collateral arteries for qRT-PCR (quantitative
real-time PCR), both hind limbs were perfused with latex ﬂexible com-
pound (Chicago Latex, Chicago, IL) via a catheter in the abdominal aorta.
For eachmouse two superﬁcial collateral arteries per sidewere isolated,
snap frozen in dry ice and stored at−80 °C until further investigations.
For histological analysis of collateral arteries, mice were perfused
with 20 ml adenosine buffer (1% adenosine (Sigma-Aldrich), 5% bovine
serum albumin (BSA, Sigma-Aldrich) dissolved in phosphate buffered
saline (PBS, PAN Biotech, Aidenbach, Germany), pH 7.4), to assure
maximum vasodilatation (Chillo et al., 2016), followed by 20 ml 4%
paraformaldehyde (PFA, Merck, Darmstadt, Germany) (for parafﬁn em-
bedding) or 20 ml 3% PFA (for cryopreservation) in PBS, pH 7.4.
For histological analysis adductor muscles were rinsed in 4%PFA for
24 h and after parafﬁn embedding cut in 4 μmcross-sections. For immu-
noﬂuorescence staining the samples were placed in 15% sucrose
(Sigma-Aldrich), dissolved in PBS, for 4 h, followed by 30% sucrose, dis-
solved in PBS, overnight at 4 °C. Afterwards the adductor muscle tissue
was cryopreserved in tissue tek (Sakura, Alphen aan den Rijn, The
Netherlands) and cut in 6 μm cross-sections.WT Md
3d
7d
a
d WT Md
Fig. 2. Collateral vessel morphology after FAL. (a) Representative pictures of Giemsa stained sl
(upper panel) and 7d (lower panel) after FAL. Scale bars: 50 μm. Bar graphs representing (b) t
and Mdk−/− collaterals 3d and 7d after FAL. 5 slices with 3 collaterals per slice were analyze
with BrdU+ ECs (arrowhead) and BrdU+ SMCs (arrow) 7d after FAL. (e) Bar graph display
collaterals 7d after FAL. 3 slices with 3 collaterals each were analyzed per mouse. n = 5. *P
Student's t-test (e). Data are means ± SD.2.4. Histology and Immuno-Histology
Parafﬁn embedded cross-sections were stained with GIEMSA ac-
cording to standard procedures. The number of collaterals on the Occ
and Sham side of WT and Mdk−/− mice was counted 7d after FAL
with an Axioskop 40 microscope and Axiocam 105 color (Carl Zeiss
AG, Feldbach, Switzerland). On theOcc side only collaterals with a lumi-
nal diameter larger than 25 μmwere deﬁned as growing collaterals. Col-
laterals with a smaller diameter were not analyzed in the following
investigations, since their diameter was comparable to the diameter of
collaterals on the Sham side and hence didn't grow after FAL (Fig. S1).
Luminal diameter and vascular wall of collateral arteries were analyzed
with AxioVs40 V4.8.2.0 software (Carl Zeiss AG). For eachmouse 5 slices
with 3 growing collaterals on each slice were measured.
Mice were treated daily with 100 μl bromodeoxyuridine (BrdU) (BD
Biosciences, San Jose, CA) (12.5mg/ml dissolved in PBS, intraperitoneal)
starting at the day of the surgical procedure. A standardized BrdU In-
SituDetection Kit (BD Biosciences)was used to analyze the proliferation
of ECs and SMCs in collateral arteries 7d after FAL. For immunoﬂuores-
cence staining 24 h after FAL, cryoﬁxed tissue sections were stained
with combinations of the following antibodies: primary anti-MK anti-
body (Cat#: PA5-19640, RRID: AB_10985009, Thermo Fischer Scientiﬁc,
Waltham, MA, dilution 1:100, for 12 h at 4 °C), or primary anti-EC SMC
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240 T. Lautz et al. / EBioMedicine 27 (2018) 237–246VEGFA164 antibody (Cat#: AF-493-SP, RRID: AB_354506, Novus
Biological, Littleton, CO, dilution 1:50, for 12 h at 4 °C), secondary
donkey anti-rabbit antibody (Cat#: A10040, RRID: AB_2534016, Ther-
mo Fischer Scientiﬁc, dilution 1:200, for 1 h at room temperature),
anti-Ly-6G antibody (Cat#: ab25024, RRID: AB_470400, Abcam, Cam-
bridge, MA, dilution 1:100, for 12 h at 4 °C) and DAPI (Cat#: D1306,
RRID: AB_2629482, Thermo Fischer Scientiﬁc, dilution 1:1000, for
20 min at room temperature). Cross-sections were covered with
Mowiol (Sigma-Aldrich) and analyzed with a confocal microscope
(Leica SP5, Leica, Wetzlar Germany).
2.5. Protein Levels of VEGFA and MK
TheVEGFAplasma levelwasmeasuredwith a standardized ELISAKit
(R&D Systems, Minneapolis, MN) following the manufacturer's proto-
col. The ready-SET-go Midkine ELISA-Kit (USCN Life Science Inc.,
Wuhan, China) was used to measure the MK plasma level following
the manufacturer's protocol.
2.6. RNA Isolation, cDNA Synthesis and qRT-PCR
After isolating RNA from collateral arteries or primary endothelial
cells with Trizol (Life technologies, Carlsbad, CA), RQ1 RNase-FreeW
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Fig. 3. Bonemarrow cell deliveredMK is essential for collateral artery growth. (a) Bar graph dis
12 h, 24 h, 3d and 7d after FAL. Dashed line shows the detection limit of the ELISA kit (0.128 ng
collaterals ofWTmice prior to any surgical procedure (basal), 12 h, 24 h and36 h after FAL as qu
triplicates. *P b 0.05, one-way ANOVAwith Bonferroni'smultiple comparison test. (c) Immunoﬂ
middle) and nuclei (DAPI, blue, lower panel, right) 24 h after FAL. Ly-6G+ cells in perivascular ti
of the collateral artery. Scale bar: 25 μm. (d) Line graph displaying the perfusion ratio (Occ/Sham
(aFAL), 3d and 7d after FAL. For the bonemarrow transplant studiesWTmice receivedMdk−/−
transplanted mice were used as control groups. n = 4 per group. §P b 0.05 (WTWT compared
(WTMdk−/− compared with Mdk−/− Mdk−/−), two-way ANOVA with Bonferroni's multiple c
marrow transplanted mice 7d after FAL. n= 4. 5 slices with 3 collaterals each were analyzed p
graph displaying the MK plasma level (ng/ml) in bone marrow transplanted mice 7d after FA
shown are means ± SD.DNase (Promega, Madison, WI) digestion was used to remove residual
genomic DNA. 250 ng puriﬁed RNA (using RNeasy MinElute columns
(Qiagen, Hilden, Germany)) was reverse transcribed into cDNA with
the QuantiTect Rev. Transcription Kit (Qiagen). For qRT-PCR analysis
the SYBR Power Green Kit (Life Technologies) was used according to
the manufacturer's protocol with 1 μl of the 1:5 diluted cDNA and 0.5
μM of each primer per reaction. For further information see the Supple-
mental Experimental Procedures.
2.7. Cell Culture
Mouse aortic ECs and SMCs were isolated as previously described
(Kobayashi et al., 2005). In brief, isolated murine aortas were ﬁlled
with collagenase type II (Biochrom AG, Berlin, Germany) solution
(2mg/ml, dissolved in serum-free Dulbecco's Modiﬁed Eagle's Medium
(DMEM, Sigma-Aldrich)) for 45 min at 37 °C, and afterwards the ECs
were ﬂushed out of the aortas with DMEM containing 20% fetal calf
serum (FCS, PAN Biotech). ECs were cultured with Complete Mouse En-
dothelial Cell Medium (Cellbiologics, Chicago, IL) on collagen A
(Biochrom AG) coated ﬂasks. The remaining aorta was cut into 2 mm
pieces and placed on a 1% gelatin-coated dish (PAN Biotech). After
10 days the tissue pieces were removed and SMCs were cultured with
Complete Mouse Smooth Muscle Cell Medium (Cellbiologics) on 1%W
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antiﬁedbyqRT-PCR. Datawere normalized to the expression level of the 18S rRNA. n=5 in
uorescence staining forMK (red, lower panel, left), neutrophils (Ly-6G, green, lower panel,
ssue stained positive for MK (upper panel). Blue dotted lines indicate the endothelial layer
) as measured by LDI in bonemarrow transplantedmice before FAL (basal), immediately
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omparison test. (e) Bar graph representing the luminal diameter of collaterals in bone
er mouse. *P b 0.05, one-way ANOVA with Bonferroni's multiple comparison test. (f) Bar
L. The dashed line shows the detection limit of the ELISA kit (0.128 ng/ml). n = 4. Data
241T. Lautz et al. / EBioMedicine 27 (2018) 237–246gelatine coated ﬂasks. Medium was changed every other day and pas-
sages 1 to 3 were used for experiments.2.8. In Vitro BrdU Proliferation Assays
A 96-well plate with 1.2 × 104 ECs or SMCs per well and a standard-
ized BrdU proliferation kit (Roche, Basel, Switzerland) was used to ana-
lyze the in vitro proliferation of isolated ECs or SMCs. For further
information see the Supplemental Experimental Procedures.2.9. Statistical Analysis
Experimenters were blind to outcome assessment for all experi-
ments. All statistical analysis were performed with GraphPad software
PRISM6 (GraphPad Software, La Jolla, CA) and are speciﬁed in the
Figure legends. Data shown are means ± SD. Results were considered
to be statistically signiﬁcant at P b 0.05.ba
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3.1. Midkine Is Essential for EC Proliferation of Growing Collateral Arteries
To characterize the functional role ofMK in arteriogenesis, we inves-
tigated a murine hindlimbmodel in which femoral artery ligation (FAL,
Occ) results in collateral artery growth (Chillo et al., 2016). Our data
showed that FAL results in a reduced increase in caliber size and tortu-
osity of superﬁcial collateral arteries as well as a signiﬁcantly reduced
perfusion recovery in Mdk deﬁcient (Mdk−/−) compared to wild-type
(WT)mice (Fig. 1a–c). To investigatewhether the reduced perfusion re-
covery observed inMdk−/−mice was due to a reduced number of pre-
existing arteriolar connections, we performed histological analyses. Our
results revealed identical numbers of collaterals with increased luminal
diameter (3 per slice per mouse) as well as total numbers of all collat-
erals (Occ = 5, Sham = 5, per slice per mouse) in WT and Mdk−/−
mice (Fig. S1). Moreover, the luminal diameters of collateral arteries of
the Sham side were comparable in WT andMdk−/−mice (Figs. S1 and
S2). However, compared to WT mice, Mdk−/− mice showed aa
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ice. Line graphs displaying the perfusion ratio (Occ/Sham) as measured by LDI inWT and
. #P b 0.05 (compared withMdk−/−), $P b 0.05 (WT+ rmMK compared withWT+ saline
graphs displaying the luminal diameter (c) and the ratio of the vascular wall to the luminal
ach were analyzed per mouse. Bar graphs displaying the percentage of BrdU+ ECs (e) and
d permouse. n=5. *P b 0.05, one-wayANOVAwith Bonferroni'smultiple comparison test.
erals 12 h after FAL as quantiﬁed by qRT-PCR. Datawere normalized to the expression level
.
242 T. Lautz et al. / EBioMedicine 27 (2018) 237–246signiﬁcantly smaller increase in luminal diameter after FAL (Fig. 2a and
b). Moreover, the ratio of the vessel wall thickness to the luminal diam-
eter was signiﬁcantly increased inMdk−/−mice (Fig. 2c). BrdU staining
revealed a signiﬁcantly decreased percentage of proliferating ECs in
Mdk−/−mice, whereas there was no signiﬁcant difference in the num-
ber of proliferating smooth muscle cells (SMCs) (Fig. 2d and e).
3.2. Leukocyte Domiciled MK Promotes Collateral Artery Growth
MK plasma levels prior to any surgical procedure (basal), 12 h and
24 h after FAL were below the detection range. At 3d after FAL,MK plas-
ma level increased to 0.268 ± 0.012 ng/ml and decreased again at 7d
(Fig. 3a). TheMdkmRNA expression levels signiﬁcantly increased in col-
laterals 12 h and 24 h after FAL (Fig. 3b). Immunoﬂuorescence double
staining against MK and Ly-6G performed on tissue samples isolated
24 h after FAL evidenced that MK is present in perivascular neutrophils
(Fig. 3c). To investigate the relevance of leukocyte derived MK, bone
marrow from WT mice was transplanted into Mdk−/− mice
(Mdk−/−WT) and vice versa (WT Mdk−/−). WTWT and Mdk−/− Mdk−/−
transplanted mice were used as control groups. Bone-marrow trans-
plantation itself didn't affect perfusion recovery, as quantiﬁed by LDI
measurements of transplanted and non-transplanted mice (Fig. S3). In
comparison to Mdk−/− Mdk−/− mice, perfusion recovery was signiﬁ-
cantly increased inMdk−/−WT as well as WT Mdk−/−mice, and reached
values of WTWT mice 7d after FAL (Fig. 3d). Histological analysis evi-
denced a signiﬁcant increase of the luminal diameter of Mdk−/−WT
mice compared to Mdk−/− Mdk−/− mice, but not in WT Mdk−/− mice
(Fig. 3e) pointing to a relevance of bone marrow cell MK for collateral
EC proliferation and hence arteriogenesis. Interestingly, MK was only70
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3.3. Rescue of Arteriogenesis in Mdk−/−Mice
In order to elucidate the function of exogenous MK on the growth of
collaterals, mice were treated with recombinant murine MK (rmMK).
Treatment with rmMK normalized perfusion recovery, the luminal di-
ameter, the ratio of the vascular wall to the luminal diameter and EC
proliferation in Mdk−/− mice, but did not inﬂuence SMC proliferation
(Fig. 4a and c–f). WT mice treated with rmMK showed signiﬁcantly in-
creased perfusion recovery 7d after FAL compared to saline treatedWT
mice, but the proliferation rate of vascular cells and the growth of collat-
eral arteries were unchanged (Fig. 4a and c–f). Thus exogenousMK im-
proved perfusion recovery in Mdk−/− mice via collateral growth,
whereas increased perfusion recovery in WT mice was due to vasodila-
tation. This data suggested thatMKnot only promotes collateral growth,
but also regulates the expression ofNos responsible for vasodilation. Ac-
cordingly,Mdk−/− andWTmice were treated with the NO-donor DETA
NONOate. In Mdk−/− mice DETA NONOate treatment signiﬁcantly in-
creased perfusion recovery and normalized EC proliferation and collat-
eral artery growth, whereas SMC proliferation was unaffected
(Fig. 4b–f). In WT mice perfusion recovery, collateral growth as well as
vascular cell proliferation was unchanged by DETA NONOate treatment
(Fig. 4b–f). qRT-PCR analysis on collaterals isolated 12 h after FAL evi-
denced signiﬁcantly decreased Nos1 and Nos3 expression levels in
Mdk−/− mice compared to WT mice, while Nos2 expression levels
showed no signiﬁcant differences (Fig. 4g). Since it is well described
that Nos3 deﬁciency is not associated with reduced collateral arteryCo
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for proper vasodilation during arteriogenesis (Troidl et al., 2010), we
asked about the relevance of Nos1 for arteriogenesis. Nos1−/− mice
did not show a reduced perfusion recovery after FAL. However, in con-
trast toWT andMdk−/−mice, NO-donor treatment strikingly interfered
with perfusion recovery in Nos1−/−mice (Fig. S4).
3.4. Inhibition of NOS Blocks the Proliferative Effect of rmMK on ECs In Vitro
Primary ECs ofMdk−/− showed signiﬁcantly reduced basal expres-
sion levels of Nos1 and Nos3 (Fig. 5a) as well as a signiﬁcantly reduced+
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Since NO has been described to induce the expression of VEGFA and
vice versa (Kroll andWaltenberger, 1998; Kimura and Esumi, 2003), we
investigated the plasma level of VEGFA ofWT andMdk−/−mice. Prior to
any surgical procedure (basal), the plasma level of VEGFAwas compara-
ble in WT andMdk−/−mice (Fig. 6a). 24 h after FAL the VEGFA plasma
level increased signiﬁcantly inWTmice, but not inMdk−/−mice. Treat-
ment with rmMK normalized the VEGFA plasma level ofMdk−/−mice,
but showed no effect on the plasma level of WT mice. DETA NONOate
treatment in contrast did not inﬂuence the plasma level of VEGFA either
in WT orMdk−/−mice. Immunohistological analysis identiﬁed neutro-
phils as potential source VEGFA (Fig. 6b).
7d after FAL, treatmentwith rmVEGFA signiﬁcantly increased perfu-
sion recovery and luminal diameter ofMdk−/−mice, however, showed
no effect on WT mice (Fig. 6c and d). Moreover, treatment with
rmVEGFA normalized Nos1 and Nos3 expression levels in collaterals of
Mdk−/−mice, whereas Nos2 expression levels were not affected either
in WT orMdk−/−mice (Fig. 6e).
Accompanying in vitro results evidenced that inhibition of VEGFR-2
by SU1498 signiﬁcantly reduced the proliferation rate of primary WT
ECs, but not of primaryMdk−/− ECs (Fig. 6f). Although having a broader
speciﬁcity, SU1498 has been used inmany experiments to blockVEGFR-
2 (e.g. (Greenberg and Jin, 2013)). Treatmentwith rmVEGFA in contrast
signiﬁcantly increased the proliferation rate of primaryWT ECs and pri-
maryMdk−/− ECs.
4. Discussion
In this studywe identiﬁedMK as factor relevant for proper collateral
EC proliferation during arteriogenesis. Our data indicate that MK regu-
lates the bioavailability of VEGFA andmodulates the differential expres-
sion ofNos1 andNos3 in vascular ECs. A proposedmodel for the action of
MK is shown in Fig. 7.
Femoral artery ligation resulted in the growth of an identical num-
ber of collateral arteries in WT andMdk−/−mice. However, the collat-
erals of Mdk−/− mice showed a reduced increase of the luminal
diameter with an increase of the ratio of vascular wall to luminal diam-
eter. Thus, perfusion recovery inMdk−/−mice was impaired due to di-
minished outward remodeling, although limited vasodilatation might
also have contributed (see below). This kind of hypertrophic outward
remodeling occurs whenever EC proliferation (intima proliferation) isFig. 7. Proposed model for the mechanistic function of midkine in arteriogenesis. After
induction of arteriogenesis, CXCL-1, either released from platelets or EC, activates
neutrophils thereby inducing MK mediated VEGFA expression and release. Upon
binding to VEGFR-2, VEGFA induces the expression of Nos1 and Nos3, relevant for
vascular cell proliferation. However, MK also activates either directly, or indirectly by
binding to ALK, PI3K resulting in NOS activation and vasodilation.compromised, while the proliferation of the media and adventitia
layer is not affected (Mulvany, 1999). Indeed, our BrdU staining re-
vealed a reduced proliferation of collateral ECs inMdk−/−mice, while
the proliferation of SMC was not negatively affected. Together, these
data identify MK as cytokine relevant for collateral EC proliferation
and conﬁrm the importance of EC proliferation for the process of
arteriogenesis (Moraes et al., 2013).
The initial phase of collateral growth relies on extravasation of
leukocytes, especially neutrophils (Chillo et al., 2016). Our immuno-
histochemical analyses together with our bone marrow transplanta-
tion experiments identiﬁed neutrophil-domiciled midkine as
relevant for arteriogenesis while non-bone marrow cell derived MK
inﬂuenced perfusion recovery by increased vasodilatation. Although
our data evidenced that MK is not released from leukocytes, thereby
conﬁrming previous results (Weckbach et al., 2012), we found in-
creased plasma levels of MK 3d and 7d after FAL. FAL results – due
to increased shear stress - in arteriogenesis in the upper leg, and
timely delayed – due to ischemia in angiogenesis in the lower leg
(Ito et al., 1997). Hypoxic ECs were recently identiﬁed as source of
soluble MK in the vascular system (Weckbach et al., 2012). Accord-
ingly it is likely that the MK observed in plasma derived from hypox-
ic ECs from the lower leg.
Treatment with rmMK restored perfusion recovery inMdk−/−mice
by promoting EC proliferation, while it promoted vasodilation in WT
mice. These results suggested that MK might be involved in regulating
NO synthases. Indeed, we found that the expression level of Nos1 and
Nos3 was signiﬁcantly reduced in ECs (but not SMCs) ofMdk−/−mice,
whereas the expression level of Nos2 was not affected. To investigate
whether reduced expression of NO synthases was causative for reduced
EC proliferation inMdk−/−mice, mice were treated with the NO-donor
DETA NONOate. Interestingly, DETA NONate treatment rescued
arteriogenesis inMdk−/− mice. In WT mice, however, DETA NONOate
treatment did not improve arteriogenesis, and in contrast to rmMK
treatment, DETA NONOate did not promote vasodilation. These data
suggest that endogenous produced NO is more effective in vasodilation
than an exogenous NO-donor. The receptors for MK are manifold
(Weckbach et al., 2011), however, it has been shown in human umbili-
cal vein endothelial cells (HUVECs) that stimulationwithMK resulted in
binding and phosphorylation of anaplastic lymphoma kinase (ALK, the
receptor for PTN (pleiotrophin)) and activation of PI3K (Stoica et al.,
2002). There is ample of evidence relating PI3K to Nos1 expression
(Fujibayashi et al., 2015) as well as to NOS1 (Wu et al., 2016) and
NOS3 (Fisslthaler et al., 2000) activation. Together, these data suggest
that ALK might have mediated the vasodilatory function of rmMK in
WT mice (see also Fig. 7). However, it might be interesting to mention
that intracellular MK is also capable to activate pI3K (Khan et al., 2017).
NO, particularly derived from NOS3 has been described to promote
EC proliferation in vitro and angiogenesis in vivo (Fukumura et al.,
2001; Cai et al., 2006; Lee et al., 1999). But studies onNos3−/−mice sug-
gested that NOS3 is not essential for arteriogenesis, and reduced perfu-
sion recoverywas attributed to reduced vasodilation (Troidl et al., 2010;
Mees et al., 2007).Nos1has previously been described to beupregulated
during arteriogenesis, however, its functional role remains to be eluci-
dated (Pagel et al., 2011). Our current study showed that reperfusion re-
covery is not reduced in Nos1−/−mice. However, in contrast to WT or
Mdk−/−mice, in which treatment with an NO-donor either did not af-
fect (WT mice) or even promoted (Mdk−/− mice) arteriogenesis, it
showed deleterious effects on perfusion recovery in Nos1−/−mice indi-
cating that the loss of NOS1 was compensated in a manner not tolerat-
ing increased levels of NO.
Whereas NOS2 and NOS3 are mainly described to be involved in NO
production, NOS1 has been more implicated in H2O2 generation
(Capettini et al., 2010; Costa et al., 2016). However, also NOS3 can gen-
erate H2O2when uncoupled (Li et al., 2002). Interestingly, NO (Cai et al.,
2006) as well as H2O2 (Oshikawa et al., 2010; Li et al., 2015) have been
shown to play a role in EC proliferation, and both NOS isoforms are
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For example it has been show in a rodent model of cerebral aneurisma
(CA) formation that expression of Nos1 (but not Nos2) was upregulated
in Nos3−/−mice (Aoki et al., 2011). Moreover, the incidence of CA for-
mation was neither affected in Nos1 nor Nos3 deﬁcient mice, however,
increased in mice deﬁcient for both genes (Aoki et al., 2011).
We have previously shown that VEGFA is not differentially
expressed in the muscle tissue surrounding growing collaterals and is
not at all expressed in collaterals (Deindl et al., 2001). Hence it was like-
ly that the increased plasma levels of VEGFA detected 24 h after induc-
tion of arteriogenesis derived from a different source. Our
immunohistological results evidenced that VEGFA is present in neutro-
phils. Interestingly, we have recently found that neutrophils are recruit-
ed to growing collaterals at the time point we now observed increased
plasma levels of VEGFA (Chillo et al., 2016). A study on mesenchymal
stem cells revealed that overexpression of MK resulted in increased
mRNA expression levels of Vegfa, as well as increased amounts of
VEGFA in cell supernatant (Zhao et al., 2014). Accordingly, our results
suggest that expression of VEGFA in neutrophils was responsible for in-
creased plasma levels of VEGFA in rmMK treatedMdk−/−mice, but also
in WT mice showing MK expression in neutrophils.
Neutrophils are well described to play an important role in angio-
genesis by supplying growth factors such as VEGFA (Gong and Koh,
2010; Scapini et al., 2004). Moreover, it has been demonstrated in a
femoral artery ligation model that angiogenesis occurring in ischemic
tissue is dependent on VEGFA released from neutrophils (Ohki et al.,
2005). We have recently shown that angiogenesis is severely compro-
mised in ischemic muscles ofMdk−/−mice after femoral artery ligation
(Weckbach et al., 2012). Together, these data suggest that MK is rele-
vant for the bioavailability of neutrophil-derived VEGFA not only in
arteriogenesis, but also in angiogenesis.
It has been shown very elegantly by Scapini in vivo (Scapini et al.,
2004) that neutrophil-derived VEGFA dependent angiogenesis is medi-
ated by CXCL-1. Moreover, it has been demonstrated by several studies
that blocking the CXCL-1 receptor CXCR2 interferes with angiogenesis
(e.g. (Sukkar et al., 2008)). Platelets, of which we have shown to play
an important role in arteriogenesis by activating neutrophils
(Chandraratne et al., 2015; Chillo et al., 2016) are a rich source of
CXCL-1. However, CXCL1, is also upregulated in ECs due to shear stress
in vitro (Hagiwara et al., 1998) and in growing collaterals in vivo (Vries
et al., 2015). Indeed it was recently demonstrated that blocking the
CXCL-1 receptor CXCR2 interferes with arteriogenesis (Vries et al.,
2015). Together these data suggest that CXCL-1 induced expression
and release of VEGFA from neutrophils is mediated by MK. A proposed
model for arteriogenesis is shown in Fig. 7.
Although not investigated in the present study, it is likely that at
later time points of arteriogenesis (d3 and d7), where monocytes play
a role (Troidl et al., 2013), VEGFA is supplied by this type of leukocyte,
since also monocytes are a source of both, MK (Badila et al., 2015) and
VEGFA (Ramanathan et al., 2003).
In our study, administration of rmVEGFA rescued arteriogenesis in
Mdk−/−mice substantiating the relationship between MK and VEGFA.
Administration of rmVEGFA to WT mice in contrast showed no effect
on arteriogenesis conﬁrming previous results (Jazwa et al., 2016). To-
gether these data suggest that MK mediated increased bioavailability
of VEGFA is necessary and sufﬁcient to promote arteriogenesis under
normal physiological conditions by regulating the expression level of
Nos1 andNos3 via activation of VEGFR-2. Increasing the current number
of mice per group (n=5 or n=4) should strengthen the data in future
studies.
In summary, we provide evidence that NO synthase, in particular
NOS1 and NOS3 isoforms are decisive for EC proliferation in
arteriogenesis. Moreover, we show that the expression of these NO
synthases is mediated by MK by increasing the bioavailability of
VEGFA. Together, these results might have profound impact on the
treatment of patients with vascular occlusive diseases.Funding Sources
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